Trial Profile
A phase II study of Sutent (SU11248) [sunitinib] as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2010
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 09 Oct 2007 New trial record.